EVOFEM BIOSCIENC(EVFM) - 2024 Q4 - Annual Results

— 2024 Net Sales Increased 6% to $19.4 Million — — Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense — Evofem Reports Fourth Consecutive Year of Net Sales Growth — Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch — SAN DIEGO, CA, March 24, 2025 — Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth ...